5:39 PM
 | 
Sep 03, 2013
 |  BC Extra  |  Company News

IQWiG rebuffs Shire's Elvanse

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said ADHD drug Elvanse lisdexamfetamine dimesylate from Shire plc (LSE:SHP; NASDAQ:SHPG) has "no...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >